Search clinical trials for: EGFR slope

Total 1651 results

AstraZeneca

Terminated

A Phase I Study of AZD1480 in Patients With Advanced Solid Malignancies and Advanced Hepatocellular Carcinoma in the Escalation Phase,Non-Small Cell Lung Cancer(NSCLC) and Non-smokers With Lung Metastasis and Gastric Cancer and Solid Tumour in the Expansion Phase.

Gastric Cancer | Advanced Solid Malignancies | Solid Tumour | Child-Pugh A to B7 Advanced Hepatocellular Carcinoma | EGFR and/or ROS Mutant NSCLC | Lung Metastasis Carcinoma

Korea, Republic of
Peking Union Medical College Hospital

Unknown

Gefitinib or Docetaxel as Second Line Therapy for Wild-type Epidermal Growth Factor Receptor (EGFR) NSCLC

Non-small Cell Lung Cancer

China
Peking Union Medical College Hospital

Unknown

Vinorelbine-ifosfamide Versus Gefitinib for EGFR Gene Mutation Negative Non-small Cell Lung Cancer Patients

Non-small Cell Lung Cancer | Effects of Chemotherapy

China
Peking Union Medical College Hospital

Unknown

Study of Chemotherapy Sequenced by or Combined With EGFR-TKIs for NSCLC Patients Failed to EGFR-TKIs Therapy

Non Small Cell Lung Cancer

China
Chinese Society of Lung Cancer

Completed

Study of Pemetrexed Versus Gefitinib in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer Who Have Previously Received Platinum-Based Chemotherapy Without Epidermal Growth Factor Receptor (EGFR) Mutations

Non Small Cell Lung Cancer

China
Jiangmen Central Hospital

Unknown

The Safety and Effects of Gefitinib in Triple-negative,EGFR Positive Metastatic Breast Cancer

Breast Cancer
National Taiwan University Hospital

Unknown

e- Ab Sensor-based Real-time Detection of Mutant EGFR in Clinical Specimens From Patients of Non-small Cell Lung Cancer

Non-small Cell Lung Cancer (NSCLC)

Taiwan
H. Lee Moffitt Cancer Center and Research Institute
Genentech, Inc.

Completed

A Phase I Trial of Capecitabine in Combination With Gemcitabine and Erlotinib for Advanced Pancreatic Cancer

Metastatic Pancreatic Carcinoma

United States
Grupo Gallego de Cancer de Pulmon
AstraZeneca; Dynamic Solutions

Unknown

Observational Study to Characterize the Incidence of EGFR Mutation Positive and Advanced NSCLC Patients

Metastatic Non-Small-Cell Lung Cancer

Spain
Inje University

Unknown

The Effect of Quetiapine XR in Depressive Patients Showing Aberrant N100 Amplitude Slope

Major Depressive Disorder

Korea, Republic of
Hadassah Medical Organization

Unknown

C11-Erlotinib PET/CT as a Tool for Identification and Characterization of Tumor With High Expression of Epidermal Growth Factor Receptor(EGFR). (EGFR; PET/CT)

Pancreatic Cancer | Lung Cancer

Israel
Spanish Lung Cancer Group
Merck Sharp & Dohme LLC

Terminated

Phase I/II of Oral Vorinostat Combination With Erlotinib in NSCLC Patients With EGFR Mutations With DP After Erlotinib.

Non-small Cell Lung Cancer

Spain
Array BioPharma

Completed

A Study of ARRY-334543 and Gemcitabine in Patients With Advanced Cancer and Pancreatic Cancer

Pancreatic Cancer | Advanced Cancer

United States
Severance Hospital
AstraZeneca

Unknown

De Novo Resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors

NSCLC
AstraZeneca

Completed

SELINE: Second-Line Iressa Phase IV Study in NSCLC Patients (SELINE)

Non Small Cell Lung Carcinoma

Korea, Republic of
Shao-quan Zhang

Unknown

Telbivudine Renoprotective Effect in Patients With HBV-related Liver Cirrhosis

HBV-related Liver Cirrhosis
AstraZeneca

Completed

Comparing Efficacy Between Anti-microtubule and Non-anti-microtubule as 3th Therapy After 2nd Line EGFR-TKI Therapy

Cancer

Taiwan
M.D. Anderson Cancer Center
Bristol-Myers Squibb

Completed

Cetuximab in Patients With Progressive or Recurrent Endometrial Cancer

Endometrial Cancer

United States
OSI Pharmaceuticals

Completed

Erlotinib vs. Standard Chemotherapy in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) and Eastern Cooperative Oncology Group (ECOG)Performance Status (PS) 2

Non-Small Cell Lung Cancer

United States
OSI Pharmaceuticals

Completed

Erlotinib (Tarceva) as a Single Agent or Intercalated With Combination Chemotherapy in Patients With EGFR Positive NSCLC

Carcinoma, Non-Small-Cell Lung

United States, United Kingdom
Ennar Pharmaceuticals AF
University of Zurich

Unknown

A Physiological Study on Downregulation of EGF-receptors in the Skin by Topical Exposition With EGF (EGFR)

Plaque Psoriasis

Switzerland
Mayo Clinic
National Cancer Institute (NCI)

Completed

Zoledronate With or Without Thalidomide in Treating Patients With Early Stage Multiple Myeloma

Multiple Myeloma and Plasma Cell Neoplasm

United States
National Cancer Institute (NCI)

Terminated

Vandetanib to Treat Women With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Ovarian Neoplasms | Fallopian Tube Neoplasms | Peritoneal Neoplasms

United States
Gustave Roussy, Cancer Campus, Grand Paris
Merck Serono International SA

Completed

Biliary Cancers: EGFR INhibitor, Gemcitabine and Oxaliplatin

Advanced Biliary Cancer

France
GlaxoSmithKline

Terminated

Lapatinib In Combination With Chemotherapy In Subjects With Relapsed Breast Cancer

Neoplasms, Breast | Relapsed Breast Cancer

United States
Dartmouth-Hitchcock Medical Center
Genentech, Inc.

Terminated

Bevacizumab (Avastin) in Unresectable/Recurrent Hemangioblastoma From Von-Hippel-Lindau Disease

Von Hippel Lindau Disease | Hemangioblastomas

United States
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Zoledronic Acid for the Treatment of Osteoporosis in Men

Osteoporosis

United States, Canada, Australia
AstraZeneca

Completed

Quetiapine XR Versus Sertraline in Acute Bipolar Depression as add-on Therapy

Bipolar Disorder | Bipolar Depression

Spain
GlaxoSmithKline

Terminated

Study of Lapatinib in Breast Cancer Patients With HER-2 Non-amplified Primary Tumors and HER-2 Positive or EGFR Positive Circulating Tumor Cells

Neoplasms, Breast

Italy, United Kingdom
Case Comprehensive Cancer Center

Terminated

Lenalidomide and Cetuximab in Treating Patients With Metastatic Colorectal Cancer

Rectal Cancer | Colon Cancer

United States
M.D. Anderson Cancer Center
OSI Pharmaceuticals

Terminated

Phase II Study of Erlotinib, an EGFR Inhibitor in Metastatic EGFR-positive 'Triple Receptor-negative' Breast Cancer

Breast Cancer

United States
Fatebenefratelli and Ophthalmic Hospital
Niguarda Hospital; Mario Negri Institute for Pharmacological Research

Unknown

Tarceva Italian Lung Optimization tRial (TAILOR)

Non Small Cell Lung Cancer (NSCLC)

Italy
Centre Hospitalier of Chartres
Hospital of Chartres- France

Completed

Study of Cetuximab in Squamous Cell Carcinoma of the Skin Expressing EGFR (CTXSCC)

Skin Diseases | Carcinoma, Squamous Cell

France
University Hospital, Antwerp
AstraZeneca; Universiteit Antwerpen

Completed

Study in NSCLC: is Timely Analysis of EGFR-mutation Status Feasible in Region Antwerp, Belgium. (HERMES)

Non Small Cell Lung Cancer

Belgium
Novartis Pharmaceuticals

Completed

Study of Oral AEE788 in Adults With Advanced Cancer

Cancer

United States
Chinese Lung Cancer Surgical Group
Zhejiang Cancer Hospital; Sun Yat-sen University; Fudan University; Chinese PLA... and other collaborators

Unknown

Erlotinib Versus Vinorelbine/Cisplatin as Adjuvant Treatment in Stage IIIA NSCLC Patients With EGFR Mutations

Non-small Cell Lung Cancer Stage IIIA

China
Genmab

Terminated

Zalutumumab in Combination With Chemotherapy and Radiotherapy in Head and Neck Cancer

Head and Neck Cancer | Squamous Cell Cancer

Belgium, Sweden, United States, France, Netherlands
National Cancer Center, Korea
Pfizer; Roche Pharma AG

Unknown

Induction Chemotherapy Followed by CCRT According to EGFR Mutation Status in NSCLC III

NSCLC | Lung Cancer

Korea, Republic of
AstraZeneca

Completed

Observations From Long Term Responders in the Gefitinib (Iressa) Expanded Access Program (EAP)

Non-Small Cell Lung Cancer

Netherlands
AVEO Pharmaceuticals, Inc.

Completed

A Safety Study of an Oral EGFR Inhibitor, AV-412, Administered Three Times Weekly in Advanced Solid Tumor Patients

Advanced Cancer | Refractory Cancer

United States
AstraZeneca

Completed

Multicentre Study to Explore the Correlation Between Smoking Pattern and Clinical Efficacy of Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI) in Male Patients

Non Small Cell Lung Cancer

Taiwan
AstraZeneca

Completed

To Study the Changes in Protein in Lung Cells of Asian Patients With Advanced Non-small Cell Lung Cancer (NSCLC) (PIONEER)

Non Small Cell Lung Cancer

Vietnam, Philippines, China, Hong Kong, Taiwan, Thailand, India
ZhuGuangYing
Zhejiang Cancer Hospital; 307 Hospital of PLA; Fudan University; Cancer Institute... and other collaborators

Unknown

Radiotherapy Combined With Iressa for EGFR Mutation Positive Patients With Locally Advanced Non-small Cell Lung Cancer (NSCLC)

Non-small Cell Lung Cancer

China
Clinical Research Center for Solid Tumor, Korea
Seoul National University Hospital; Korean Cancer Study Group

Terminated

A Study to Assess the Efficacy of Erlotinib for Leptomeningeal Carcinomatosis in EGFR Mutation Positive Non-small Cell Lung Cancer

Non-small Cell Lung Cancer | Leptomeningeal Carcinomatosis

Korea, Republic of
YM BioSciences

Completed

Phase 2 Study of Nimotuzumab in Pediatric Recurrent Diffuse Intrinsic Pontine Glioma

Recurrent Diffuse Pontine Gliomas

United States, Canada, Israel
Peking Union Medical College Hospital
Peking University People's Hospital

Unknown

A Retrospective EGFR Mutation Status Study in Chinese NSCLC Patients Using Paired Plasma and Tissue Samples

Carcinoma, Non-Small-Cell Lung

China
Maria Sklodowska-Curie National Research Institute...

Unknown

Pre-emptive Low-dose Doxycycline During Anti-EGFR Treatment (STLDD-1)

Colorectal Cancer | Skin Toxicities

Poland
Provitro GmbH
Charite University, Berlin, Germany; AstraZeneca

Completed

Pathomolecular Analysis of Rare EGFR Mutations in Advanced NSCLC

Mutations in Exons 18 to 21

Germany
Allergan

Terminated

A Phase II Study of ACZONE™ (Dapsone) Gel, 5% As a Treatment For Tarceva® (Erlotinib)Related Rash

Rash | Non-small-Cell Lung Cancer

United States
Eli Lilly and Company
Bristol-Myers Squibb

Completed

Erbitux (Cetuximab) Given Alone to Patients With EGFR-Negative Metastatic Colon or Rectal Cancer That is Refractory to Chemotherapy

Colorectal Neoplasms | Neoplasm | Metastases

United States, Canada

3

Subscribe